COMMUNIQUÉS West-GlobeNewswire
-
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
26/03/2026 -
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
26/03/2026 -
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
26/03/2026 -
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
26/03/2026 -
Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
26/03/2026 -
CMR Surgical Announces 45,000 Patients Treated Globally as Robotic-Assisted Surgery Company Makes Its U.S. Debut
26/03/2026 -
HNL Lab Medicine Earns Record 12 Reputation 800 Awards for Patient Experience Excellence
26/03/2026 -
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
26/03/2026 -
Geron Announces Appointment of New Members to its Board of Directors
26/03/2026 -
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
26/03/2026 -
Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
26/03/2026 -
Firefly Confirms Public-Private Partnership with the Department of War
26/03/2026 -
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
26/03/2026 -
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
26/03/2026 -
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
26/03/2026 -
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/03/2026 -
HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
26/03/2026 -
Hyperion DeFi Reports 4Q and FY 2025 Financial Results with Quarter-over-Quarter Growth of +64% Revenue and +87% Adjusted Gross Profit
26/03/2026 -
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
26/03/2026
Pages